According to a recent LinkedIn post from Resolution Therapeutics, the company plans to attend the American Society of Gene & Cell Therapy 29th Annual Meeting in Boston in May 2026. The post highlights that SVP and Head of Research and Translational Science Lara Campana is scheduled to deliver an oral presentation on key preclinical data for its lead candidate RTX001.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post indicates that RTX001 is being positioned as a regenerative macrophage therapy for end-stage liver disease, with the preclinical work to be discussed in a session focused on novel T-cell and myeloid strategies. The post further notes that RTX001 is already under evaluation in the Phase I/II EMERALD clinical trial, suggesting clinical progress that investors may view as an important validation point for the company’s platform.
For investors, participation in a prominent industry meeting such as ASGCT may enhance Resolution Therapeutics’ visibility among scientific and potential partnering audiences. The spotlight on both preclinical data and an ongoing Phase I/II study could signal a path toward future value inflection events, contingent on safety and efficacy outcomes as well as potential strategic collaborations or funding aligned with the EMERALD trial’s progress.